Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2004 3
2005 2
2008 1
2009 1
2011 1
2013 1
2015 1
2016 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.
Ustun C, Arock M, Kluin-Nelemans HC, Reiter A, Sperr WR, George T, Horny HP, Hartmann K, Sotlar K, Damaj G, Hermine O, Verstovsek S, Metcalfe DD, Gotlib J, Akin C, Valent P. Ustun C, et al. Haematologica. 2016 Oct;101(10):1133-1143. doi: 10.3324/haematol.2016.146563. Haematologica. 2016. PMID: 27694501 Free article. Review.
Systemic mastocytosis is a heterogeneous disease characterized by the accumulation of neoplastic mast cells in the bone marrow and other organ organs/tissues. Mutations in KIT, most frequently KIT D816V, are detected in over 80% of all systemic mast
Systemic mastocytosis is a heterogeneous disease characterized by the accumulation of neoplastic mast cells in the bone
Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis.
Sperr WR, Horny HP, Valent P. Sperr WR, et al. Int Arch Allergy Immunol. 2002 Feb;127(2):140-2. doi: 10.1159/000048186. Int Arch Allergy Immunol. 2002. PMID: 11919425 Review.
Systemic mastocytosis (SM) is a myeloproliferative disease affecting multipotent and/or mast cell-committed hematopoietic progenitor cells. In a significant subgroup of patients (10-35%), an associated clonal hematologic non
Systemic mastocytosis (SM) is a myeloproliferative disease affecting multipotent and/or mast cell-committed hema
Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment.
Azaña JM, Torrelo A, Matito A. Azaña JM, et al. Actas Dermosifiliogr. 2016 Jan-Feb;107(1):15-22. doi: 10.1016/j.ad.2015.09.009. Epub 2015 Oct 30. Actas Dermosifiliogr. 2016. PMID: 26525106 Free article. Review. English, Spanish.
The systemic variants in this classification are as follows: indolent systemic mastocytosis (SM), aggressive SM, SM with an associated clonal hematological non-mast cell lineage disease, mast cell
The systemic variants in this classification are as follows: indolent systemic mastocytosis (SM), aggressive SM, SM wit …
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
Verstovsek S. Verstovsek S. Eur J Haematol. 2013 Feb;90(2):89-98. doi: 10.1111/ejh.12043. Eur J Haematol. 2013. PMID: 23181448 Free PMC article. Review.
Apart from indolent systemic mastocytosis (SM), which is associated with a favorable prognosis, other subtypes of SM (SM with associated clonal hematologic non-mast cell lineage disease, aggressive SM, a …
Apart from indolent systemic mastocytosis (SM), which is associated with a favorable prognosis, other subtypes of SM (S …
Mastocytosis.
Metcalfe DD. Metcalfe DD. Novartis Found Symp. 2005;271:232-42; discussion 242-9. Novartis Found Symp. 2005. PMID: 16605139 Review.
Systemic mastocytosis (SM) is a persistent disease. A somatic c-kit mutation at codon 816 is often detectable in haematopoietic cells. The clinical course of mastocytosis is variable, ranging from indolent to aggressive. Five categories of disease
Systemic mastocytosis (SM) is a persistent disease. A somatic c-kit mutation at codon 816 is often detectable in haemat
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C, DeRemer DL, Akin C. Ustun C, et al. Leuk Res. 2011 Sep;35(9):1143-52. doi: 10.1016/j.leukres.2011.05.006. Epub 2011 Jun 8. Leuk Res. 2011. PMID: 21641642 Review.
Systemic mastocytosis (SM) is a heterogeneous disease, vast majority of these patients have a gain of function mutation in the gene encoding the tyrosine kinase KIT (KIT(D816V)). ...The data from these studies indicate that, apart from KIT(D816V), other kinas
Systemic mastocytosis (SM) is a heterogeneous disease, vast majority of these patients have a gain of function mutation
Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.
Simon J, Lortholary O, Caillat-Vigneron N, Raphaël M, Martin A, Brière J, Barète S, Hermine O, Casassus P; Group AFIRMM (Association française pour les initiatives de recherche sur le mastocyte et les mastocytoses). Simon J, et al. Pathol Biol (Paris). 2004 Jun;52(5):294-9. doi: 10.1016/j.patbio.2004.04.012. Pathol Biol (Paris). 2004. PMID: 15217717 Review.
Systemic mastocytosis (SM) are defined by an abnormal growth and accumulation of mast cells in bone marrow and/or other extracutaneous organs. ...Long-term therapy should be offered to patients with initial positive response. To control more aggressive SM or mast
Systemic mastocytosis (SM) are defined by an abnormal growth and accumulation of mast cells in bone marrow and/or other extrac
Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM. Valent P, et al. Leuk Res. 2001 Jul;25(7):603-25. doi: 10.1016/s0145-2126(01)00038-8. Leuk Res. 2001. PMID: 11377686 Review.
Systemic mastocytosis (SM) is commonly seen in adults and defined by multifocal histological lesions in the bone marrow (affected almost invariably) or other extracutaneous organs (major criteria) together with cytological and biochemical signs (minor criteria) of
Systemic mastocytosis (SM) is commonly seen in adults and defined by multifocal histological lesions in the bone marrow (affec
[Current concepts and treatment advances in systemic mastocytosis].
Georgin-Lavialle S, Barete S, Suarez F, Lepelletier Y, Bodemer C, Dubreuil P, Lortholary O, Hermine O. Georgin-Lavialle S, et al. Rev Med Interne. 2009 Jan;30(1):25-34. doi: 10.1016/j.revmed.2008.01.025. Epub 2008 Apr 10. Rev Med Interne. 2009. PMID: 18406017 Review. French.
Systemic mastocytosis is regressive among children, whereas the disease is persistent among adults. A clonal haematological non-mast cell lineage disease can be associated. ...
Systemic mastocytosis is regressive among children, whereas the disease is persistent among adults. A clonal
Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny HP, Bennett JM. Valent P, et al. Leuk Res. 2001 Jul;25(7):595-602. doi: 10.1016/s0145-2126(01)00040-6. Leuk Res. 2001. PMID: 11377685 Review.
Based on clonal evolution, biology of afflicted cells, and disease criteria, three major groups of patients have been recognized: The first meets criteria for both diagnoses 'systemic mastocytosis' and 'associated hematologic clonal
Based on clonal evolution, biology of afflicted cells, and disease criteria, three major groups of patients have been recogniz …
14 results